Share Price and Basic Stock Data
Last Updated: October 15, 2024, 11:08 pm
PEG Ratio | -2.34 |
---|
Competitors of Nath Bio-Genes (India) Ltd
Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
---|---|---|---|---|---|---|---|---|---|
Genomic Valley Biotech Ltd | 28.2 Cr. | 92.4 | 92.4/21.0 | 109 | 12.5 | 0.00 % | 0.57 % | 0.57 % | 10.0 |
Genesis IBRC India Ltd | 20.6 Cr. | 15.8 | 15.8/9.73 | 3.79 | 0.00 % | 54.8 % | 54.8 % | 10.0 | |
Shreeoswal Seeds & Chemicals Ltd | 227 Cr. | 24.8 | 59.6/23.0 | 4.39 | 0.00 % | 0.62 % | 9.84 % | 2.00 | |
Nath Bio-Genes (India) Ltd | 394 Cr. | 207 | 264/167 | 10.0 | 321 | 0.97 % | 6.85 % | 6.23 % | 10.0 |
Continental Seeds and Chemicals Ltd | 55.3 Cr. | 50.2 | 70.2/18.0 | 12.7 | 0.00 % | 10.0 % | 18.0 % | 10.0 | |
Industry Average | 310.50 Cr | 78.04 | 59.50 | 70.88 | 0.19% | 14.57% | 17.89% | 8.40 |
Quarterly Result
Month | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 36.96 | 54.91 | 215.11 | 15.24 | 21.94 | 27.21 | 209.39 | 21.73 | 25.30 | 44.92 | 235.28 | 22.57 | 31.74 |
Expenses | 29.65 | 43.88 | 166.58 | 10.44 | 15.65 | 48.47 | 174.91 | 16.98 | 19.68 | 40.84 | 198.26 | 17.48 | 25.96 |
Operating Profit | 7.31 | 11.03 | 48.53 | 4.80 | 6.29 | -21.26 | 34.48 | 4.75 | 5.62 | 4.08 | 37.02 | 5.09 | 5.78 |
OPM % | 19.78% | 20.09% | 22.56% | 31.50% | 28.67% | -78.13% | 16.47% | 21.86% | 22.21% | 9.08% | 15.73% | 22.55% | 18.21% |
Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -88.05 | 0.00 | 0.20 | 0.06 | 0.26 | 0.12 | 0.06 | 2.54 |
Interest | 2.10 | 2.73 | 2.66 | 2.78 | 2.70 | 2.47 | 2.88 | 2.75 | 2.96 | 1.53 | 2.76 | 2.44 | 2.84 |
Depreciation | 0.67 | 0.81 | 0.68 | 0.68 | 0.68 | 1.05 | 0.67 | 0.67 | 0.67 | 0.99 | 0.76 | 0.76 | 0.76 |
Profit before tax | 4.54 | 7.49 | 45.19 | 1.34 | 2.91 | -112.83 | 30.93 | 1.53 | 2.05 | 1.82 | 33.62 | 1.95 | 4.72 |
Tax % | 6.39% | 4.67% | 0.62% | 8.21% | 3.44% | -3.07% | 0.55% | 3.92% | 34.15% | 12.64% | 0.65% | 17.95% | 16.31% |
Net Profit | 4.25 | 7.14 | 44.91 | 1.23 | 2.81 | -116.29 | 30.76 | 1.47 | 1.35 | 1.59 | 33.40 | 1.60 | 3.96 |
EPS in Rs | 2.24 | 3.76 | 23.63 | 0.65 | 1.48 | -61.19 | 16.19 | 0.77 | 0.71 | 0.84 | 17.58 | 0.84 | 2.08 |
Last Updated: Unknown
Profit & Loss - Annual Report
Last Updated: Unknown
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 97 | 109 | 136 | 143 | 127 | 142 | 171 | 206 | 246 | 271 | 230 | 234 | 335 |
Expenses | 82 | 89 | 102 | 109 | 103 | 113 | 131 | 163 | 191 | 204 | 193 | 185 | 283 |
Operating Profit | 15 | 20 | 34 | 35 | 25 | 29 | 40 | 43 | 55 | 67 | 37 | 49 | 52 |
OPM % | 15% | 18% | 25% | 24% | 19% | 20% | 24% | 21% | 22% | 25% | 16% | 21% | 16% |
Other Income | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | -87 | 1 | 3 |
Interest | 2 | 4 | 4 | 5 | 6 | 10 | 10 | 5 | 7 | 9 | 11 | 10 | 10 |
Depreciation | 5 | 5 | 5 | 4 | 4 | 3 | 1 | 1 | 1 | 3 | 3 | 3 | 3 |
Profit before tax | 9 | 12 | 26 | 26 | 15 | 17 | 30 | 39 | 49 | 57 | -63 | 36 | 42 |
Tax % | -1% | 4% | 5% | 4% | 6% | 3% | 2% | 1% | -4% | 2% | -6% | 3% | |
Net Profit | 9 | 12 | 24 | 25 | 14 | 16 | 29 | 38 | 50 | 56 | -67 | 35 | 41 |
EPS in Rs | 5.75 | 7.34 | 15.18 | 15.87 | 8.85 | 10.17 | 15.48 | 20.22 | 26.56 | 29.29 | -35.43 | 18.51 | 21.34 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 7% | -6% | 11% |
YoY Net Profit Growth
Year | 2012-2013 | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 33.33% | 100.00% | 4.17% | -44.00% | 14.29% | 81.25% | 31.03% | 31.58% | 12.00% | -219.64% | 152.24% |
Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -95.83% | -48.17% | 58.29% | 66.96% | -50.22% | 0.54% | -19.58% | -231.64% | 371.88% |
Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 4% |
3 Years: | -3% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | -1% |
3 Years: | -13% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | -9% |
3 Years: | -14% |
1 Year: | -6% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 7% |
3 Years: | 6% |
Last Year: | 6% |
Last Updated: Unknown
Balance Sheet
Last Updated: Unknown
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 | 19 | 19 | 19 | 19 | 19 | 19 | 19 |
Reserves | 41 | 66 | 91 | 105 | 287 | 450 | 489 | 539 | 594 | 523 | 554 | 592 |
Borrowings | 19 | 23 | 22 | 59 | 74 | 33 | 58 | 70 | 101 | 93 | 105 | 108 |
Other Liabilities | 67 | 85 | 97 | 87 | 78 | 69 | 80 | 102 | 75 | 105 | 114 | 158 |
Total Liabilities | 143 | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 |
Fixed Assets | 18 | 17 | 13 | 30 | 207 | 211 | 232 | 246 | 247 | 245 | 244 | 249 |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 |
Other Assets | 120 | 168 | 208 | 231 | 243 | 355 | 409 | 479 | 538 | 490 | 544 | 622 |
Total Assets | 143 | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 |
Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | 15.00 | 1.00 | 11.00 | 13.00 | -34.00 | -45.00 | 7.00 | -15.00 | -15.00 | -34.00 | -56.00 | -56.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 70 | 95 | 114 | 130 | 133 | 175 | 191 | 159 | 147 | 136 | 152 | 139 |
Inventory Days | 3,840 | 4,743 | 4,388 | |||||||||
Days Payable | 1,309 | 1,406 | 586 | |||||||||
Cash Conversion Cycle | 70 | 95 | 114 | 130 | 2,665 | 3,512 | 191 | 159 | 147 | 136 | 3,954 | 139 |
Working Capital Days | 167 | 179 | 242 | 383 | 398 | 515 | 544 | 519 | 585 | 573 | 578 | 498 |
ROCE % | 24% | 33% | 26% | 14% | 10% | 9% | 8% | 9% | 10% | 5% | 7% | 7% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
Aditya Birla Sun Life Pure Value Fund | 828,595 | 0.32 | 16.53 | 828,595 | 2024-10-13 | 0% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 13 | Mar 12 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 21.34 | 18.43 | -35.55 | 7.34 | 5.75 |
Diluted EPS (Rs.) | 21.34 | 18.43 | -35.55 | 7.34 | 5.75 |
Cash EPS (Rs.) | 22.56 | 20.01 | -33.84 | 10.16 | 8.69 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 320.94 | 301.60 | 285.16 | 35.91 | 28.57 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 320.94 | 301.60 | 285.16 | 35.91 | 28.57 |
Revenue From Operations / Share (Rs.) | 175.03 | 158.58 | 146.47 | 86.04 | 77.43 |
PBDIT / Share (Rs.) | 26.57 | 25.94 | 20.54 | 12.80 | 10.61 |
PBIT / Share (Rs.) | 24.85 | 24.36 | 18.92 | 9.98 | 7.67 |
PBT / Share (Rs.) | 21.87 | 19.03 | -33.38 | 7.68 | 6.54 |
Net Profit / Share (Rs.) | 20.85 | 18.42 | -35.46 | 7.34 | 5.75 |
NP After MI And SOA / Share (Rs.) | 20.85 | 18.42 | -35.46 | 7.34 | 5.75 |
PBDIT Margin (%) | 15.17 | 16.35 | 14.02 | 14.87 | 13.70 |
PBIT Margin (%) | 14.19 | 15.35 | 12.91 | 11.59 | 9.90 |
PBT Margin (%) | 12.49 | 12.00 | -22.78 | 8.92 | 8.45 |
Net Profit Margin (%) | 11.91 | 11.61 | -24.20 | 8.52 | 7.42 |
NP After MI And SOA Margin (%) | 11.91 | 11.61 | -24.20 | 8.52 | 7.42 |
Return on Networth / Equity (%) | 6.49 | 6.10 | -12.43 | 20.43 | 20.12 |
Return on Capital Employeed (%) | 7.64 | 8.03 | 6.59 | 26.54 | 25.62 |
Return On Assets (%) | 4.50 | 4.41 | -9.11 | 7.42 | 7.67 |
Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
Total Debt / Equity (X) | 0.17 | 0.18 | 0.17 | 0.31 | 0.19 |
Asset Turnover Ratio (%) | 0.39 | 0.39 | 0.00 | 1.05 | 0.00 |
Current Ratio (X) | 2.18 | 2.41 | 2.41 | 1.22 | 1.34 |
Quick Ratio (X) | 1.30 | 1.45 | 1.27 | 0.43 | 0.42 |
Inventory Turnover Ratio (X) | 0.65 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend Payout Ratio (NP) (%) | 0.00 | 10.85 | -5.64 | 0.00 | 0.00 |
Dividend Payout Ratio (CP) (%) | 0.00 | 9.99 | -5.91 | 0.00 | 0.00 |
Earning Retention Ratio (%) | 0.00 | 89.15 | 105.64 | 0.00 | 0.00 |
Cash Earning Retention Ratio (%) | 0.00 | 90.01 | 105.91 | 0.00 | 0.00 |
Interest Coverage Ratio (X) | 5.54 | 4.87 | 3.68 | 5.58 | 9.40 |
Interest Coverage Ratio (Post Tax) (X) | 4.97 | 4.46 | 3.02 | 4.20 | 6.87 |
Enterprise Value (Cr.) | 358.27 | 336.48 | 494.22 | 0.00 | 0.00 |
EV / Net Operating Revenue (X) | 1.08 | 1.12 | 1.78 | 0.00 | 0.00 |
EV / EBITDA (X) | 7.10 | 6.83 | 12.66 | 0.00 | 0.00 |
MarketCap / Net Operating Revenue (X) | 0.99 | 0.89 | 1.46 | 0.00 | 0.00 |
Retention Ratios (%) | 0.00 | 89.14 | 105.64 | 0.00 | 0.00 |
Price / BV (X) | 0.54 | 0.46 | 0.74 | 0.00 | 0.00 |
Price / Net Operating Revenue (X) | 0.99 | 0.89 | 1.46 | 0.00 | 0.00 |
EarningsYield | 0.11 | 0.13 | -0.16 | 0.00 | 0.00 |
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nath Bio-Genes (India) Ltd:
- Net Profit Margin: 11.91%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.64% (Industry Average ROCE: 14.57%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.49% (Industry Average ROE: 17.89%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 10 (Industry average Stock P/E: 23.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.91%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Seeds/Tissue Culture/Bio Technology | Nath House, Nath Road, Aurangabad Maharashtra 431005 | investor@nathbiogenes.com http://www.nathbiogenes.com |
Management | |
---|---|
Name | Position Held |
Mr. Satish Kagliwal | Managing Director |
Mr. Madhukar Deshpande | Director |
Ms. Ashu Jain | Director |
Mrs. Jeevanlata Kagliwal | Director |
Mr. Vadla Nagabhushanam | Director |
Mr. Hitesh Purohit | Director |
Mr. Akash Kagliwal | Director |
FAQ
What is the latest fair value of Nath Bio-Genes (India) Ltd?
The latest fair value of Nath Bio-Genes (India) Ltd is ₹201.92.
What is the Market Cap of Nath Bio-Genes (India) Ltd?
The Market Cap of Nath Bio-Genes (India) Ltd is 394 Cr..
What is the current Stock Price of Nath Bio-Genes (India) Ltd as on 15 October 2024?
The current stock price of Nath Bio-Genes (India) Ltd as on 15 October 2024 is ₹207.
What is the High / Low of Nath Bio-Genes (India) Ltd stocks in FY 2024?
In FY 2024, the High / Low of Nath Bio-Genes (India) Ltd stocks is 264/167.
What is the Stock P/E of Nath Bio-Genes (India) Ltd?
The Stock P/E of Nath Bio-Genes (India) Ltd is 10.0.
What is the Book Value of Nath Bio-Genes (India) Ltd?
The Book Value of Nath Bio-Genes (India) Ltd is 321.
What is the Dividend Yield of Nath Bio-Genes (India) Ltd?
The Dividend Yield of Nath Bio-Genes (India) Ltd is 0.97 %.
What is the ROCE of Nath Bio-Genes (India) Ltd?
The ROCE of Nath Bio-Genes (India) Ltd is 6.85 %.
What is the ROE of Nath Bio-Genes (India) Ltd?
The ROE of Nath Bio-Genes (India) Ltd is 6.23 %.
What is the Face Value of Nath Bio-Genes (India) Ltd?
The Face Value of Nath Bio-Genes (India) Ltd is 10.0.